Skip to content
Clinical Trials – home
Therapeutic area

Blood and lymphatic system disorders – page 23

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Study of azacitidine combined with low-dose venetoclax treatment for patients with acute myeloid leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Rigshospitalet

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pyruvic Acid
  • Sponsor:Rigshospitalet

Myelofibrosis+1

Recruiting

Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effects of Infusing Modified CD34+ Cells for Patients with Fanconi Anemia Subtype A

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Autologous Cd34+Enriched Cells From Patients With Fanconi Anemia Subtype A Transduced Ex Vivo With Lentiviral Vector Carrying The Fanconi Anemia Complementation Group A Gene
  • Sponsor:Rocket Pharmaceuticals Inc.

Study comparing ferumoxytol and iron sucrose for treating iron deficiency anemia in children

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years
  • Substances:Ferumoxytol
  • Sponsor:Amag Pharmaceuticals Inc.

Lymphangiosarcoma+34

Recruiting

Study of trabectedin alone versus trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ttf-Ngr
  • Sponsor:Universitaet Muenster

Comparing ferumoxytol and iron sucrose for treating iron deficiency anemia in children with chronic kidney disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ferumoxytol
  • Sponsor:Amag Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study of pegcetacoplan safety and effectiveness in adolescents aged 12-17 with paroxysmal nocturnal hemoglobinuria

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

B-cell lymphoma+1

Recruiting

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:LYSARC

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier De Versailles

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.